Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2714124 | 0.78 | KMT2A (0.56) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL15565804 | 0.78 | MEN1 (0.38) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL3257090 | 0.77 | KMT2A (0.46) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL18712760 | 0.77 | AHR (0.39) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL13500430 | 0.77 | MEN1 (0.38) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL19725082 | 0.75 | MEN1 (0.49) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL6524904 | 0.75 | KMT2A (0.44) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL5416326 | 0.75 | MEN1 (0.44) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL29495709 | 0.75 | KMT2A (0.44) | KMT2AMEN1MAPTLMNAKDM4E | |
| SCHEMBL4775824 | 0.75 | MEN1 (0.41) | KMT2AMEN1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200115347-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| EP-1595869-A1 | PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005095359-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1565475-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| EP-1485390-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004046152-A1 | DIAZINOPYRIMIDINES | F. HOFFMANN LA ROCHE AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2003-11-06 | — | — | US | disclosed |
| WO-2003074530-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885MEN1 4113/4885MAPT 4089/4885 |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KMT2A 3752/4885MEN1 4354/4885MAPT 4848/4885 |
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885MEN1 4113/4885MAPT 4089/4885 |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | P2RX3, P2RX2, P2RX1 | KMT2A 4013/4885MEN1 4379/4885MAPT 4524/4885 |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885MEN1 4113/4885MAPT 4089/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KMT2A 3752/4885MEN1 4354/4885MAPT 4848/4885 |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885MEN1 4113/4885MAPT 4089/4885 |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAPKAPK2 | KMT2A 2559/4885MEN1 4549/4885MAPT 2536/4885 |
| US-20200115347-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885MEN1 4113/4885MAPT 4089/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | KMT2A 3530/4885MEN1 3017/4885MAPT 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.